ClinicalTrials.Veeva

Menu

Acute Pharmacokinetic and Pharmacodynamic Effects of "Tobacco-Free" Oral Nicotine Pouches in Smokers

Johns Hopkins University logo

Johns Hopkins University

Status and phase

Enrolling
Phase 1

Conditions

Nicotine Addiction
Drug Effect
Nicotine Withdrawal

Treatments

Other: Cigarette
Other: Nicotine

Study type

Interventional

Funder types

Other
NIH

Identifiers

NCT05335915
1R01DA055962-01 (Other Grant/Funding Number)
IRB00318560

Details and patient eligibility

About

The purpose of the present study is to examine the pharmacokinetics and pharmacodynamics of "tobacco-free" oral nicotine pouches, at various doses and flavors, in healthy adult smokers. The study will utilize a within-subjects, double-blind design. Upon enrollment, participants will complete 7 dosing conditions: tobacco-flavored pouch (low or high nicotine dose), mint/menthol-flavored pouch (low or high nicotine dose), and fruit-flavored pouch (low or high nicotine dose); participants will also complete a condition where the participants will smoke participants' preferred brand of cigarettes. In each experimental session, participants will complete 2 product-use bouts. In bout 1, the participants will use a single product (pouch or cigarette) for a fixed period under controlled conditions. In bout 2, participants will be given 2 hours to use participants' assigned product ad libitum.

Full description

The purpose of the present study is to examine the pharmacokinetics and pharmacodynamics of "tobacco-free" oral nicotine pouches, at various doses and flavors, in healthy adult smokers. The study will utilize a within-subjects, double-blind design. Upon enrollment, participants will complete 7 dosing conditions: tobacco-flavored pouch (low or high nicotine dose), mint/menthol-flavored pouch (low or high nicotine dose), and fruit-flavored pouch (low or high nicotine dose); participants will also complete a condition where the participants will smoke participants' preferred brand of cigarettes. In each experimental session, participants will complete 2 product-use bouts. In bout 1, the participants will use a single product (pouch or cigarette) for a fixed period under controlled conditions. In bout 2, participants will be given 2 hours to use participants' assigned product ad libitum. Blood specimens will be obtained throughout the sessions to characterize the pharmacokinetics of nicotine and various pharmacodynamic outcomes (subjective drug effects, tobacco withdrawal symptoms, vital signs) will also be assessed. These procedures will be completed 7 separate times (on separate visits) by each participant (sessions will be separated by at least 48 hours).

Enrollment

90 estimated patients

Sex

All

Ages

21+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  1. ≥ 21 years old
  2. good general health based on screening procedures (e.g., physical exam, blood testing)
  3. vital signs in normal range (resting heart rate less than 100bpm, systolic blood pressure less than 150mmHg, diastolic blood pressure less than 90mmHg)
  4. negative urine test for illicit drug use (excluding THC) and negative breath alcohol test at screening and before each session
  5. self-report currently smoking daily
  6. self-report at least a one year history of regular smoking
  7. exhaled breath CO greater than or equal to 10ppm and urine cotinine greater than 100 ng/ml at screening
  8. meet criteria for at least mild tobacco use disorder
  9. no self-reported regular use of other tobacco products (e.g., smokeless products, e-cigarettes) in the past 30 days
  10. no self-reported prior use of novel oral nicotine pouches
  11. exhaled breath CO less than 10 ppm upon arrival for each study session.

Exclusion criteria

  1. Psychoactive drug use (aside from cannabis, nicotine, alcohol, or caffeine) in past month
  2. Current use of over-the-counter (OTC) drugs, supplements/vitamins, or prescription medications that, in the opinion of the investigators or medical staff, will impact safety
  3. Use of cannabis >4 times per week
  4. History of or current significant medical condition that, in the opinion of the investigators or medical staff, will impact safety
  5. Current psychiatric condition or substance use disorder (aside from tobacco use disorder) that, in the opinion of the investigators or medical staff, will impact safety or study outcomes
  6. Women who are pregnant, planning to become pregnant, or are breast-feeding
  7. Currently seeking treatment to quit smoking or currently using a nicotine/tobacco cessation product.
  8. Enrollment in another clinical trial in the past 30 days

Trial design

Primary purpose

Basic Science

Allocation

Randomized

Interventional model

Crossover Assignment

Masking

Double Blind

90 participants in 7 patient groups

Original/Tobacco Flavored Pouch (low nicotine dose)
Experimental group
Description:
participants will use a tobacco flavored pouch (4mg nicotine dose)under both controlled (experimenter-directed) and ad libitum use conditions
Treatment:
Other: Nicotine
Original/Tobacco Flavored Pouch (high nicotine dose)
Experimental group
Description:
participants will use a tobacco flavored pouch (8mg nicotine dose)under both controlled (experimenter-directed) and ad libitum use conditions
Treatment:
Other: Nicotine
Mint/Menthol Flavored Pouch (low nicotine dose)
Experimental group
Description:
participants will use a mint/menthol flavored pouch (4mg nicotine dose)under both controlled (experimenter-directed) and ad libitum use conditions
Treatment:
Other: Nicotine
Mint/Menthol Flavored Pouch (high nicotine dose)
Experimental group
Description:
participants will use a mint/menthol flavored pouch (8mg nicotine dose)under both controlled (experimenter-directed) and ad libitum use conditions
Treatment:
Other: Nicotine
Fruit Flavored Pouch (low nicotine dose)
Experimental group
Description:
participants will use a fruit flavored pouch (4mg nicotine dose)under both controlled (experimenter-directed) and ad libitum use conditions
Treatment:
Other: Nicotine
Fruit Flavored Pouch (high nicotine dose)
Experimental group
Description:
participants will use a fruit flavored pouch (8mg nicotine dose)under both controlled (experimenter-directed) and ad libitum use conditions
Treatment:
Other: Nicotine
Own brand cigarettes
Active Comparator group
Description:
participants will smoke participants' own brand of cigarettes under both controlled (experimenter-directed) and ad libitum use conditions
Treatment:
Other: Cigarette

Trial contacts and locations

1

Loading...

Central trial contact

Tory Spindle, PhD; Mikahla McDeavitt

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems